Business
Morison launches its exclusive CSR platform ‘Suwa Deya’, reaffirming its purpose of ‘Making Premium Healthcare Affordable’
Morison Ltd., a pioneer in pharma manufacturing with a solid footprint of over 60 years industry expertise, and a subsidiary of the Hemas Group, recently unveiled its exclusive CSR platform Suwa Deya, going one step beyond its purpose of ‘Making Premium Healthcare Affordable’.
Being an exemplary corporate citizen in the industry, Morison firmly believes in taking the high road through uncompromised integrity across its value chain. Within this framework, Morison engages its stakeholders through a novel approach in its pharma brand building journey. With this emerged Suwa Deya the exclusive CSR platform of Morison, extending a series of meaningful and differentiated industry related activities to give back to society. Through Suwa Deya, Morison aspires to touch the lives of many by launching a spectrum of unique initiatives dedicated towards patients, employees, general public and healthcare professionals, being its key stakeholders.
Patient centricity being its core footing, Suwa Deya commenced by acknowledging an unseen need of patients visiting Government Hospital diabetic clinics.
Realising that the patients visiting the clinics arrive early without a proper morning meal, the first initiative of Suwa Deya attempted to address this by providing healthy breakfast snacks and beverages for such patients. Sensitive to the inconveniences patients undergo, particularly during the prevailing economic challenges, Morison has conducted 15 such programs at multiple diabetic clinics, including Kalubowila Teaching Hospital, Balangoda Base Hospital, Rathnapura Teaching Hospital and Negombo District General Hospital.
Taking it another step further, the ‘Ape Suwa Deya’ initiative was launched as a distinctive extension of Suwa Deya, to serve the Morison team and their closest family members. Ape Suwa Deya offers EmpaMor (Empagliflozin 10mg & 25mg), MinMor (Metformin 500mg) and Ros-10 (Rosuvastatin 10mg), three of Morison’s latest branded pharmaceuticals to treat Diabetes and Cardiovascular diseases, the two most prevalent non communicable diseases in the country. Morison employees and their loved ones who have been prescribed such products, are entitled to receive these completely free of charge on a monthly basis throughout their employment period, ensuring they do not shoulder the economic burden of chronic disease.
Dinesh Athapaththu, Managing Director, Morison Limited commenting on the programme said, “In making our purpose a reality, our own team who enables it on the ground by moving on to uncomfortable territories and getting the ball rolling during the toughest of times, comes first. Therefore, in Suwa Deya, all of us at Morison undoubtedly deserve a special place. With that emerged “Ape Suwa Deya”, to serve our very own team and their loved ones with our own medicine manufactured at our own premises, completely free of charge.”
Morison aims to further develop Suwa Deya into a comprehensive CSR platform to foster hope for all its key stakeholders with more differentiated interventions in the future, while driving the local pharmaceutical industry to the heights it deserves.
In the recent past, Morison has come forward to progressively change the trajectory of the pharma manufacturing industry in Sri Lanka. The recent inauguration of its second pharma manufacturing facility at Homagama, a state-of-the-art worldclass facility built as per EU GMP specifications, was one major milestone towards embarking on its new journey.
Being a truly Sri Lankan company, Morison takes pride in nurturing an exclusive homegrown pharmaceutical brand which is built upon a value blend that is uniquely unparalleled. The new branded pharma range of Morison stays true to its purpose of “Making Premium Healthcare Affordable”, extending the best worlds of quality and price, assuredly a rare combination in the market.
Dr. R. A. D. Jeewantha was honoured as the Most Innovative Dentist of the Year at the Business World International Awards, 2025. Organised by the Business World International Organisation, the award ceremony was held recently at the Mount Lavinia Hotel. A graduate of the Faculty of Dental Sciences, University of Peradeniya, Dr. Jeewantha has built a reputation as one of Sri Lanka’s most respected and forward-thinking dental surgeons. After gaining vital experience in Government hospitals, including the Teaching Hospital in Karapitiya, he also served at a leading private hospital before launching his own practice—Doctor J Premium Dental Care in Delkanda, Nugegoda.
His dental clinic is known for offering advanced, patient-focused treatments in restorative dentistry, cosmetic procedures, and implantology, using state-of-the-art technology. Dr. Jeewantha is especially skilled in dental implants, having completed the American Residency Course in Dental Implantology at Roseman University, accredited by the American Academy of Implant Dentistry. Dr. Jeewantha holds fellowships from the International College of Continuing Dental Education (FICCDE) and the Pierre Fauchard Academy (USA). His advanced skills include modern root canal treatments using Mineral Trioxide Aggregate (MTA) for both surgical and non-surgical procedures.
He has completed international trainings in digital dentistry, full-arch implantology techniques like All-on-Four and Zygomatic Systems, and smile design using digital 3D scans. He has participated in global dental events such as the Asia-Pacific Dental Congress and completed training at institutions including the University of Manchester and North Western State Medical University in Russia. His courses have covered everything from intraoral scanning to managing tooth wear. He has previously received many local and international awards. Dr. Jeewantha also serves the community as a Justice of the Peace for All Island.
The Foundation in Biological Studies at IIHS provides a unique alternative for students looking to fast-track their health careers after their Ordinary Level (O/L) exams. This programme offers a direct route to global health careers, bypassing traditional A/Ls. With over 1,000 students already advancing to universities in Australia, the UK, and Finland, IIHS has positioned the course as a reliable launchpad for careers in fields like medicine, nursing, biomedical sciences, and digital health. “This programme is a game-changer, offering a transformative journey into global healthcare education,” said IIHS CEO Dr. Kithsiri Edirisinghe.
Seylan Bank has recorded a Profit before Tax (PBT) of LKR 4,199 million in Q1 2025, marking a 13.36% growth compared to LKR 3,704 million in Q1 2024. Profit after Tax (PAT) rose by 20.29%, reaching LKR 2,761 million, up from LKR 2,295 million in the corresponding period of 2024.
Despite a decrease in net interest income by 8.37% due to market interest rate reductions, the bank’s net fee-based income grew by 13.83%, driven by fees from loans, cards, remittances, and other services. Total operating income for the quarter was LKR 11,258 million, a 3.83% decrease from the previous year, while operating expenses rose by 4.62%, largely due to increased personnel and other operating costs.
Impairment charges were significantly reduced by 83.17%, totaling LKR 262 million, reflecting the bank’s solid credit quality and proactive provisions. The bank’s impaired loan ratio improved to 1.98% from 2.10% in Q1 2024, with a provision cover ratio of 80.74%.
Seylan Bank’s total assets grew to LKR 785 billion, with loans and advances reaching LKR 469 billion and deposits totaling LKR 647 billion. The bank’s capital adequacy ratios remained strong, with the Common Equity Tier 1 Capital Ratio at 13.67% and Total Capital Ratio at 17.64%.
In addition to its financial performance, Seylan Bank continued its commitment to education, opening 16 more “Seylan Pahasara Libraries,” bringing the total to 281 libraries across the island.Fitch Ratings upgraded Seylan Bank’s National Long-Term Rating to ‘A+(lka)’ with a Stable Outlook in January 2025, further underscoring the bank’s financial stability and growth trajectory.
-
Features5 days agoRuGoesWild: Taking science into the wild — and into the hearts of Sri Lankans
-
News5 days agoOrders under the provisions of the Prevention of Corruptions Act No. 9 of 2023 for concurrence of parliament
-
Features6 days agoNew species of Bronzeback snake, discovered in Sri Lanka
-
News4 days agoProf. Rambukwella passes away
-
News6 days agoPhoto of Sacred tooth relic: CID launches probe
-
Opinion5 days agoSri Lanka’s Foreign Policy amid Geopolitical Transformations: 1990-2024 – Part IX
-
Features6 days agoSri Lanka’s Foreign Policy amid Geopolitical Transformations: 1990-2024 – Part VIII
-
Features2 days agoThe Truth will set us free – I